var data={"title":"Vecuronium: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Vecuronium: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/7146?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=vecuronium-drug-information\" class=\"drug drug_general\">see &quot;Vecuronium: Drug information&quot;</a> and <a href=\"topic.htm?path=vecuronium-patient-drug-information\" class=\"drug drug_patient\">see &quot;Vecuronium: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5708859\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Experienced personnel:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">This drug should be administered by adequately trained individuals familiar with its actions, characteristics, and hazards.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F233672\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Norcuron&reg;</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1062905\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Neuromuscular Blocker Agent, Nondepolarizing</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Skeletal Muscle Relaxant, Paralytic</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11445265\" class=\"block don drugH1Div\"><span class=\"drugH1\">Dosing: Neonatal</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Paralysis/skeletal muscle relaxation:</b> Limited data available:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Intermittent IV: 0.1 mg/kg/dose (Kumar 2010); maintenance: 0.03 to 0.15 mg/kg/dose every 1 to 2 hours as needed (Costarino 1987)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Continuous IV infusion: Initial: 1.7 <b>mcg</b>/kg/minute (0.1 mg/kg/<b>hour</b>) (Fitzpatrick 1991; Reich 2004); titrate until desired neuromuscular blockade is achieved; some investigators have suggested adjusting rates in 25% to 100% increments (Reich 2004); doses ranging from 1.2 to 3 <b>mcg</b>/kg/minute (0.07 to 0.18 mg/kg/<b>hour</b>) have been reported (Fitzpatrick 1991)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1062898\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=vecuronium-drug-information\" class=\"drug drug_general\">see &quot;Vecuronium: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric: <b>Note:</b> Dose to effect; doses will vary due to interpatient variability.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Paralysis/skeletal muscle relaxation: </b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Manufacturer's labeling: Surgical relaxation, tracheal intubation: Infants &gt;7 weeks, Children, and Adolescents: IV: 0.08 to 0.1 mg/kg; <b>Note:</b> If intubation is performed using succinylcholine, the initial dose of vecuronium may be reduced to 0.04 to 0.06 mg/kg with inhalation anesthesia and 0.05 to 0.06 mg/kg with balanced anesthesia. Children 1 to 10 years may require slightly higher initial doses and more frequent supplementation.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Alternate dosing (Martin 1999; Playfor 2007):</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Infants:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">IV: 0.08 to 0.1 mg/kg/dose; repeat as needed </p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Continuous IV infusion: 0.8 to 1.7 <b>mcg</b>/kg/minute (0.05 to 0.1 mg/kg/<b>hour</b>) </p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Children and Adolescents: </p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">IV: 0.08 to 0.1 mg/kg/dose; repeat as needed </p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Continuous IV infusion: 0.8 to 2.5 <b>mcg</b>/kg/minute (0.05 to 0.15 mg/kg/<b>hour</b>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult: Dose to effect; doses will vary due to interpatient variability.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Surgical relaxation:</b> IV (do not administer IM): </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Tracheal intubation: IV: Initial: 0.08 to 0.1 mg/kg. <b>Note:</b> If intubation is performed using succinylcholine, the initial dose of vecuronium may be reduced to 0.04 to 0.06 mg/kg with inhalation anesthesia and 0.05 to 0.06 mg/kg with balanced anesthesia.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Obesity:</i> For obese (&ge;130% of IBW) adult patients, may use ideal body weight (IBW) (Erstad 2004; Schwartz 1992; Weinstein 1988); onset time may be slightly delayed using IBW.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Maintenance for continued surgical relaxation (only after return of neuromuscular function): Intermittent dosing: 0.01 to 0.015 mg/kg <b>or</b> continuous infusion of 0.8 to 1.2 <b>mcg</b>/kg/minute (0.048 to 0.072 mg/kg/<b>hour</b>). <b>Note:</b> Use lower end of the dosing range when anesthesia is maintained with an inhaled anesthetic agent, with the redosing interval guided by monitoring with a peripheral nerve stimulator.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>ICU paralysis (eg, facilitate mechanical ventilation) in selected adequately sedated patients</b> (Darrah 1989; Greenberg 2013; Murray 2002; Rudis 1997): IV: Initial bolus dose: 0.08 to 0.1 mg/kg, then a continuous IV infusion of 0.8 to 1.7 <b>mcg</b>/kg/minute (0.048 to 0.102 mg/kg/<b>hour</b>); monitor depth of blockade every 1 to 2 hours initially until stable dose, then every 8 to 12 hours. Usual maintenance infusion dose range: 0.8 to 1.2 <b>mcg</b>/kg/minute (0.048 to 0.072 mg/kg/<b>hour</b>). </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Dosage adjustment</i> (Rudis 1996; Rudis 1997): Adjust rate of administration in increments of 0.3 <b>mcg</b>/kg/minute (or 0.018 mg/kg/<b>hour</b>) or by 50% reductions of previous dose according to peripheral nerve stimulation response or desired clinical response. Discontinue infusion if neuromuscular function does not return.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <b>Note:</b> When possible, minimize depth and duration of paralysis. Stopping the infusion daily for some time until forced to restart based on patient condition is recommended to reduce postparalytic complications (eg, acute quadriplegic myopathy syndrome [AQMS]) (Murray 2002; Segredo 1992).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Intermittent bolus dosing</i> (Hunter 1985): 0.1 to 0.2 mg/kg/dose; may be repeated when neuromuscular function returns</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment:</b> There are no dosage adjustments provided in manufacturer&rsquo;s labeling. However, patients with renal impairment do not experience clinically significant prolongation of neuromuscular blockade with vecuronium; however, in patients who are anephric, the clinical duration is prolonged. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment:</b> There are no dosage adjustments provided in manufacturer's labeling; however, dose reductions may be necessary in patients with liver disease.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F233649\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous, as bromide: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 100 mg/100 mL in NaCl 0.9% (100 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Prefilled Syringe, Intravenous, as bromide: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 10 mg/10 mL (10 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Intravenous, as bromide: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 10 mg (1 ea); 20 mg (1 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Intravenous, as bromide [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 10 mg (1 ea); 20 mg (1 ea)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F233635\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1062908\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Parenteral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IV bolus: Administer undiluted (reconstituted solution at 1 mg/mL) by rapid direct injection </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Continuous IV infusion:  Administer via an infusion pump at a concentration not to exceed 1 mg/mL</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14473226\" class=\"block uicn drugH1Div\"><span class=\"drugH1\">Usual Infusion Concentrations: Neonatal</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>IV infusion:</b> 1 mg/mL</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14473225\" class=\"block uicp drugH1Div\"><span class=\"drugH1\">Usual Infusion Concentrations: Pediatric</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>IV infusion:</b> 0.1 mg/mL, 0.2 mg/mL, 1 mg/mL</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F233665\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;display:inline\">Store intact vials of powder for injection at room temperature 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F). Vials reconstituted with bacteriostatic water for injection (BWFI) may be stored for 5 days under refrigeration or at room temperature. Vials reconstituted with other compatible diluents (including D5W, D5NS, LR, NS) should be stored under refrigeration and used within 24 hours.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1062907\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Adjunct to anesthesia, to facilitate endotracheal intubation, and provide skeletal muscle relaxation during surgery or mechanical ventilation (FDA approved in ages &gt;7 weeks to 16 years and adults)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F233715\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Vecuronium may be confused with valproate sodium, vancomycin </p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Norcuron may be confused with Narcan</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High alert medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs which have a heightened risk of causing significant patient harm when used in error.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Other safety concerns:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">United States Pharmacopeia (USP) 2006: The Interdisciplinary Safe Medication Use Expert Committee of the USP has recommended the following:</p>\n        <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">- Hospitals, clinics, and other practice sites should institute special safeguards in the storage, labeling, and use of these agents and should include these safeguards in staff orientation and competency training.</p>\n        <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">- Healthcare professionals should be on high alert (especially vigilant) whenever a neuromuscular-blocking agent (NMBA) is stocked, ordered, prepared, or administered.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F233712\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">Rare but important or life-threatening: Bradycardia, circulatory shock, edema, flushing, hypersensitivity reaction (including erythema, hypotension, tachycardia, urticaria), pruritus, skin rash</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F233655\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to vecuronium or any component of the formulation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F233639\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Neuromuscular cross-sensitivity: Cross-sensitivity with other neuromuscular-blocking agents may occur; use extreme caution in patients with previous anaphylactic reactions.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Prolonged paralysis: Some patients may experience delayed recovery of neuromuscular function after administration (especially after prolonged use). Other factors associated with delayed recovery should be considered (eg, corticosteroid use, disease-related conditions).  </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Burn injury: Resistance may occur in burn patients (&ge;20% of total body surface area), usually several days after the injury, and may persist for several months after wound healing (Han, 2009). </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Conditions which may <i>antagonize</i> neuromuscular blockade: Respiratory alkalosis, hypercalcemia, demyelinating lesions, peripheral neuropathies, denervation, and muscle trauma may result in antagonism of neuromuscular blockade (Greenberg, 2013; Miller, 2010; Murray, 2002; Naguib, 2002).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Conditions which may <i>potentiate</i> neuromuscular blockade: Electrolyte abnormalities (eg, severe hypocalcemia, severe hypokalemia, hypermagnesemia), neuromuscular diseases, metabolic acidosis, metabolic alkalosis, respiratory acidosis, Eaton-Lambert syndrome, and myasthenia gravis may result in potentiation of neuromuscular blockade (Greenberg, 2013; Miller, 2010; Naguib, 2002). </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hepatic impairment: Use with caution in patients with hepatic impairment; clinical duration may be prolonged. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Renal impairment: In general, patients with renal impairment do not experience clinically significant prolongation of neuromuscular blockade with vecuronium; however, in patients who are anephric, the clinical duration may be prolonged.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Respiratory disease: Use with caution in patients with underlying respiratory disease. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Corticosteroids: In addition to prolonging recovery from neuromuscular blockade, concomitant use with corticosteroids has been associated with development of acute quadriplegic myopathy syndrome (AQMS). Current guidelines recommend neuromuscular blockers be discontinued as soon as possible in patients receiving corticosteroids or interrupted daily until necessary to restart them based on clinical condition (Murray, 2002).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; High potential for interactions: Numerous drugs either <i>antagonize</i> (eg, acetylcholinesterase inhibitors) or <i>potentiate</i> (eg, calcium channel blockers, certain antimicrobials, inhalation anesthetics) the effects of neuromuscular blockade; use with caution in patients receiving these agents.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Elderly: Use with caution in the elderly, effects and duration are more variable; dosage reduction may be considered.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Immobilized patients: Resistance may occur in patients who are immobilized.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Pediatric: Children 1-10 years of age may require slightly higher initial doses and slightly more frequent supplementation.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Benzyl alcohol and derivatives: Diluent may contain benzyl alcohol; large amounts of benzyl alcohol (&ge;99 mg/kg/day) have been associated with a potentially fatal toxicity (&ldquo;gasping syndrome&rdquo;) in neonates; the &ldquo;gasping syndrome&rdquo; consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse (AAP [&quot;Inactive&quot; 1997]; CDC, 1982); some data suggests that benzoate displaces bilirubin from protein binding sites (Ahlfors, 2001); avoid or use dosage forms containing benzyl alcohol with caution in neonates. See manufacturer&rsquo;s labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Appropriate use: Maintenance of an adequate airway and respiratory support is critical. Vecuronium does not relieve pain or produce sedation; use should include appropriate anesthesia, pain control, and sedation.  In patients requiring long-term administration, use of a peripheral nerve stimulator to monitor drug effects is strongly recommended. Additional doses of vecuronium or any other neuromuscular-blocking agent should be avoided unless nerve stimulation response suggests inadequate neuromuscular blockade. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Experienced personnel: <b>[US Boxed Warning]: Should be administered by adequately trained individuals familiar with its use.</b></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13300211\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F233643\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=12877&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">AbobotulinumtoxinA: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Acetylcholinesterase Inhibitors: May diminish the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amifampridine: Neuromuscular-Blocking Agents may diminish the therapeutic effect of Amifampridine. Amifampridine may diminish the therapeutic effect of Neuromuscular-Blocking Agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aminoglycosides: May enhance the respiratory depressant effect of Neuromuscular-Blocking Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bacitracin (Systemic): May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bromperidol: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Calcium Channel Blockers: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Capreomycin: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CarBAMazepine: May decrease the serum concentration of Vecuronium.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiac Glycosides: Neuromuscular-Blocking Agents may enhance the arrhythmogenic effect of Cardiac Glycosides. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Clindamycin (Topical): May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Colistimethate: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Corticosteroids (Systemic): Neuromuscular-Blocking Agents (Nondepolarizing) may enhance the adverse neuromuscular effect of Corticosteroids (Systemic). Increased muscle weakness, possibly progressing to polyneuropathies and myopathies, may occur. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CycloSPORINE (Systemic): May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dantrolene: May enhance the neuromuscular-blocking effect of Vecuronium.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fosphenytoin-Phenytoin: May diminish the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing). Fosphenytoin-Phenytoin may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing). Fosphenytoin-Phenytoin may decrease the serum concentration of Neuromuscular-Blocking Agents (Nondepolarizing).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Inhalational Anesthetics: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ketorolac (Nasal): May enhance the adverse/toxic effect of Neuromuscular-Blocking Agents (Nondepolarizing). Specifically, episodes of apnea have been reported in patients using this combination.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ketorolac (Systemic): May enhance the adverse/toxic effect of Neuromuscular-Blocking Agents (Nondepolarizing). Specifically, episodes of apnea have been reported in patients using this combination.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lincosamide Antibiotics: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lithium: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Local Anesthetics: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.<b> Exceptions: </b>Benzocaine; Benzydamine; Cocaine (Topical); Dibucaine; Dyclonine; Ethyl Chloride; Hexylresorcinol; Lidocaine (Ophthalmic); Lidocaine (Topical); Pramoxine; Proparacaine; Tetracaine (Ophthalmic); Tetracaine (Topical).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Loop Diuretics: May diminish the neuromuscular-blocking effect of Neuromuscular-Blocking Agents. Loop Diuretics may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Magnesium Salts: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MetroNIDAZOLE (Systemic): May enhance the neuromuscular-blocking effect of Vecuronium.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Minocycline: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">OnabotulinumtoxinA: Neuromuscular-Blocking Agents may enhance the neuromuscular-blocking effect of OnabotulinumtoxinA. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pholcodine: May enhance the adverse/toxic effect of Neuromuscular-Blocking Agents. Specifically, anaphylaxis has been reported.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Piperacillin: May enhance the neuromuscular-blocking effect of Vecuronium.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Polymyxin B: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Procainamide: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QuiNIDine: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QuiNINE: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">RimabotulinumtoxinB: Neuromuscular-Blocking Agents may enhance the neuromuscular-blocking effect of RimabotulinumtoxinB. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Spironolactone: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tetracyclines: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Trimebutine: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vancomycin: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F233645\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F233658\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Animal reproduction studies have not been conducted. The pharmacokinetics of vecuronium are altered during pregnancy. Use in cesarean section has been reported; umbilical venous concentrations were 11% of maternal values at delivery. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1062904\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Assisted ventilation status, heart rate, blood pressure, peripheral nerve stimulator measuring twitch response</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F233638\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Blocks acetylcholine from binding to receptors on motor endplate inhibiting depolarization</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F233654\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Onset of action: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Good intubation conditions: Within 2.5-3 minutes </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Maximum neuromuscular blockade: Within 3-5 minutes </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Duration: Under balanced anesthesia (time to recovery to 25% of control): 25-40 minutes; recovery 95% complete ~45-65 minutes after injection of intubating dose</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: V<sub>d</sub>: 0.3-0.4 L/kg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: 60% to 80%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Active metabolite: 3-desacetyl vecuronium (<sup>1</sup>/<sub>2</sub> the activity of parent drug) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life, elimination: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Infants: 65 minutes </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Children: 41 minutes </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Healthy adult surgical patients and renal failure patients undergoing transplant surgery: 65-75 minutes; Late pregnancy: 35-40 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life, distribution: Adults: 4 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Primarily feces (40% to 75%); urine (30% as unchanged drug and metabolites); the rate of elimination is appreciably reduced with hepatic dysfunction but not with renal dysfunction </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16324085\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Vecuronium Bromide-NaCl Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg/100 mL 0.9% (100 mL): $126.40</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Vecuronium Bromide Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg (1): $6.00</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 mg (1): $12.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution Prefilled Syringe</b> (Vecuronium Bromide (PF) Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg/10 mL (10 mL): $18.79</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F233659\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Curon (BD);</li>\n      <li>Ecron (ID);</li>\n      <li>Neovec (ET, LK);</li>\n      <li>Nodescron (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Nodescr&oacute;n (MX);</li>\n      <li>Nor Q (BD);</li>\n      <li>Norcuron (AE, AR, AT, AU, BE, BG, BH, CH, CL, CN, CY, CZ, DE, DK, EE, EG, ES, FI, FR, GB, GR, HK, HN, HR, HU, ID, IL, IN, IQ, IR, IT, JO, KR, KW, LB, LU, LY, MT, MX, NL, NO, NZ, OM, PE, PK, PL, PT, QA, RU, SA, SE, SI, SK, SY, TH, TR, VE, VN, YE);</li>\n      <li>Survec (BD, LK);</li>\n      <li>Vecural (PY, UY);</li>\n      <li>Vecure (AU);</li>\n      <li>Vecuron (BD, BR, PH)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. <i>J Pediatr</i>. 2001;139(2):317-319.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vecuronium-pediatric-drug-information/abstract-text/11487763 /pubmed\" target=\"_blank\" id=\"11487763 \">11487763 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics Committee on Drugs. &quot;Inactive&quot; ingredients in pharmaceutical products: update (subject review). <i>Pediatrics</i>. 1997;99(2):268-278.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vecuronium-pediatric-drug-information/abstract-text/9024461/pubmed\" target=\"_blank\" id=\"9024461\">9024461</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol - United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982;31(22):290-291. Available at <a href=\"http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm\" target=\"_blank\">http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm</a><span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vecuronium-pediatric-drug-information/abstract-text/6810084 /pubmed\" target=\"_blank\" id=\"6810084 \">6810084 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Costarino AT, Polin RA. Neuromuscular relaxants in the neonate. <i>Clin Perinatol</i>. 1987;14(4):965-989. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vecuronium-pediatric-drug-information/abstract-text/2827933 /pubmed\" target=\"_blank\" id=\"2827933 \">2827933 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Darrah WC, Johnston JR, Mirakhur RK, &ldquo;Vecuronium Infusions for Prolonged Muscle Relaxation in the Intensive Care Unit,&rdquo; <i>Crit Care Med</i>, 1989, 17(12):1297-300.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vecuronium-pediatric-drug-information/abstract-text/2574099/pubmed\" target=\"_blank\" id=\"2574099\">2574099</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Erstad BL, &ldquo;Dosing of Medications in Morbidly Obese Patients in the Intensive Care Unit Setting,&rdquo; <i>Intensive Care Med</i>, 2004, 30(1):18-32.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vecuronium-pediatric-drug-information/abstract-text/14625670/pubmed\" target=\"_blank\" id=\"14625670\">14625670</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fisher DM, Castagnoli K, Miller RD. Vecuronium kinetics and dynamics in anesthetized infants and children. <i>Clin Pharmacol Ther</i>. 1985;37(4):402-406.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vecuronium-pediatric-drug-information/abstract-text/2858278 /pubmed\" target=\"_blank\" id=\"2858278 \">2858278 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fitzpatrick KT, Black GW, Crean PM, Mirakhur RK. Continuous vecuronium infusion for prolonged muscle relaxation in children. <i>Can J Anaesth</i>. 1991;38(2):169-174.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vecuronium-pediatric-drug-information/abstract-text/1673644 /pubmed\" target=\"_blank\" id=\"1673644 \">1673644 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Greenberg SB, Vender J. The use of neuromuscular blocking agents in the ICU: where are we now? <i>Crit Care Med</i>. 2013;41(5):1332-1344.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vecuronium-pediatric-drug-information/abstract-text/23591211/pubmed\" target=\"_blank\" id=\"23591211\">23591211</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Han TH, Martyn JAJ. Onset and effectiveness of rocuronium for rapid onset of paralysis in patients with major burns: priming or large bolus. <i>Br J Anaesth</i>. 2009;102(1):55-60.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vecuronium-pediatric-drug-information/abstract-text/19029093/pubmed\" target=\"_blank\" id=\"19029093\">19029093</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hunter JM, Parker CJR, Bess CF, et al, &ldquo;The Use of Different Doses of Vecuronium in Patients With Liver Dysfunction,&rdquo; <i>Br J Anaesth</i>, 1985, 57(8):758-64.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vecuronium-pediatric-drug-information/abstract-text/2861836/pubmed\" target=\"_blank\" id=\"2861836\">2861836</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kumar P, Denson SE, Mancuso TJ, et al, &quot;Premedication for Nonemergency Endotracheal Intubation in the Neonate,&quot; <i>Pediatrics</i>, 2010, 125(3):608-15.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vecuronium-pediatric-drug-information/abstract-text/20176672/pubmed\" target=\"_blank\" id=\"20176672\">20176672</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Martin LD, Bratton SL, and O'Rourke PP, &ldquo;Clinical Uses and Controversies of Neuromuscular Blocking Agents in Infants and Children,&rdquo; <i>Crit Care Med</i>, 1999, 27(7):1358-68.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vecuronium-pediatric-drug-information/abstract-text/10446832/pubmed\" target=\"_blank\" id=\"10446832\">10446832</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Murray MJ, Cowen J, DeBlock H, et al, &ldquo;Clinical Practice Guidelines for Sustained Neuromuscular Blockade in the Adult Critically Ill Patient. Task Force of the American College of Critical Care Medicine (ACCM) of the Society of Critical Care Medicine (SCCM), American Society of Health-System Pharmacists, American College of Chest Physicians,&rdquo; <i>Crit Care Med</i>, 2002, 30(1):142-56.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vecuronium-pediatric-drug-information/abstract-text/11902255/pubmed\" target=\"_blank\" id=\"11902255\">11902255</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Murray KL, Wright D, Laxton B, Miller KM, Meyers J, Englebright J. Implementation of standardized pediatric i.v. medication concentrations.<i> Am J Health Syst Pharm</i>. 2014;71(17):1500-1508.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vecuronium-pediatric-drug-information/abstract-text/25147175 /pubmed\" target=\"_blank\" id=\"25147175 \">25147175 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Phillips MS, &quot;Standardizing I.V. Infusion Concentrations: National Survey Results,&quot; <i>Am J Health Syst Pharm</i>, 2011, 68(22):2176-82.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vecuronium-pediatric-drug-information/abstract-text/22058104/pubmed\" target=\"_blank\" id=\"22058104\">22058104</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Reich DL, Hollinger I, Harrington DJ, Seiden HS, Chakravorti S, Cook DR. Comparison of cisatracurium and vecuronium by infusion in neonates and small infants after congenital heart surgery. <i>Anesthesiology</i>. 2004;101(5):1122-1127.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vecuronium-pediatric-drug-information/abstract-text/15505447 /pubmed\" target=\"_blank\" id=\"15505447 \">15505447 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rudis MI, Guslits BG, Zarowitz BJ. Technical and interpretive problems of peripheral nerve stimulation in monitoring neuromuscular blockade in the intensive care unit.<i> Ann Pharmacother</i>. 1996;30(2):165-172. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vecuronium-pediatric-drug-information/abstract-text/8835051 /pubmed\" target=\"_blank\" id=\"8835051 \">8835051 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rudis MI, Sikora CA, Angus E, et al, &ldquo;A Prospective, Randomized, Controlled Evaluation of Peripheral Nerve Stimulation Versus Standard Clinical Dosing of Neuromuscular Blocking Agents in Critically Ill Patients,&rdquo; <i>Crit Care Med</i>, 1997, 25(4), 575-83.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vecuronium-pediatric-drug-information/abstract-text/9142020/pubmed\" target=\"_blank\" id=\"9142020\">9142020</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Schwartz AE, Matteo RS, Ornstein E, et al, &ldquo;Pharmacokinetics and Pharmacodynamics of Vecuronium in the Obese Surgical Patient,&rdquo; <i>Anesth Analg</i>, 1992, 74(4):515-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vecuronium-pediatric-drug-information/abstract-text/1348166/pubmed\" target=\"_blank\" id=\"1348166\">1348166</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Segredo V, Caldwell JE, Matthay MA, et al, &ldquo;Persistent Paralysis in Critically Ill Patients After Long-term Administration of Vecuronium,&rdquo; <i>N Engl J Med</i>, 1992, 327(8):524-28.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vecuronium-pediatric-drug-information/abstract-text/1353252/pubmed\" target=\"_blank\" id=\"1353252\">1353252</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sinclair-Pingel J, Grisso AG, Hargrove FR, Wright L. Implementation of standardized concentrations for continuous infusions using a computerized provider Oder Entry System [published correction appears in  <i>Hosp Pharm</i>. 2007;42:84-85]. <i>Hosp Pharm</i>. 2006;41(11):1102-1106. </div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Vecuronium [prescribing information]. Lake Forest, IL: Hospira, Inc; May 2012.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Weinstein JA, Matteo RS, Ornstein E, et al, &ldquo;Pharmacodynamics of Vecuronium and Atracurium in the Obese Surgical Patient,&rdquo; <i>Anesth Analg</i>, 1988, 67(12):1149-53.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vecuronium-pediatric-drug-information/abstract-text/2904232/pubmed\" target=\"_blank\" id=\"2904232\">2904232</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 12877 Version 131.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F5708859\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F233672\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1062905\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Neonatal\" href=\"#F11445265\" class=\"outlineLink\">Dosing: Neonatal</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1062898\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F233649\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F233635\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1062908\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Usual Infusion Concentrations: Neonatal\" href=\"#F14473226\" class=\"outlineLink\">Usual Infusion Concentrations: Neonatal</a></li><li class=\"plainItem\"><a sectionName=\"Usual Infusion Concentrations: Pediatric\" href=\"#F14473225\" class=\"outlineLink\">Usual Infusion Concentrations: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F233665\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1062907\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F233715\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F233712\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F233655\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F233639\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13300211\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F233643\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F233645\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F233658\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1062904\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F233638\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F233654\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16324085\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F233659\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/12877|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=vecuronium-drug-information\" class=\"drug drug_general\">Vecuronium: Drug information</a></li><li><a href=\"topic.htm?path=vecuronium-patient-drug-information\" class=\"drug drug_patient\">Vecuronium: Patient drug information</a></li></ul></div></div>","javascript":null}